Interpace Biosciences (OTCMKTS:IDXG) Stock Crosses Above Two Hundred Day Moving Average – Here’s What Happened
by Michael Walen · The Markets DailyShares of Interpace Biosciences, Inc. (OTCMKTS:IDXG – Get Free Report) crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $1.59 and traded as high as $1.76. Interpace Biosciences shares last traded at $1.76, with a volume of 3,012 shares.
Interpace Biosciences Stock Performance
The company has a market capitalization of $7.75 million, a price-to-earnings ratio of -35.00 and a beta of 0.59. The company’s fifty day simple moving average is $1.92 and its two-hundred day simple moving average is $1.60.
Interpace Biosciences (OTCMKTS:IDXG – Get Free Report) last announced its quarterly earnings data on Tuesday, May 12th. The business services provider reported $0.03 earnings per share for the quarter. The company had revenue of $9.03 million during the quarter. Interpace Biosciences had a net margin of 65.25% and a return on equity of 219.07%.
About Interpace Biosciences
Interpace Biosciences, Inc provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer.